Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

Andrew J. Wagner; William D. Tap; Sebastian Bauer; Jean Yves Blay; Jayesh Desai; Hans Gelderblom; Emanuela Palmerini; Christopher W. Ryan; Charles Peterfy; John H. Healey; Michiel A. J. van de Sande; Meng Qian; Dale E. Shuster; Abdul Waheed Rajper; Xin Ye; Kristen M. Tecson; Margaret Wooddell; Silvia Stacchiotti

doi:10.1093/oncolo/oyae345

Related publications

Article2024

Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.

William D. Tap, Vivek A. Bhadri, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Fiona Zarins, B. Harrow, Maitreyi G. Sharma, Rodrigo Ruiz‐Soto, Matthew L. Sherman, Jean Yves Blay, Hans Gelderblom

Article2025

A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).

Hans Gelderblom, Emanuela Palmerini, Jean Yves Blay, Michiel A. J. van de Sande, Javier Martín‐Broto, Raúl Terés, M. B. Davies, Elyse Seltzer, S. Veltkamp, Gabriel Tinoco

Article2025

Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.

Vivek A. Bhadri, Hans Gelderblom, Silvia Stacchiotti, Sebastian Bauer, Andrew J. Wagner, Michiel A. J. van de Sande, Nicholas M. Bernthal, Antonio López–Pousa, Albiruni Ryan Abdul Razak, Antoîne Italiano, Mahbubl Ahmed, Axel Le Cesne, Christopher Tait, Amanda Saunders, Nicholas Zeringo, B. Harrow, Maitreyi G. Sharma, Matthew L. Sherman, Jean Yves Blay, William D. Tap

Article2021

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.

Anthony B. El-Khoueiry, Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, Armando Santoro, Bruno Sangro, Ignacio Melero, Masatoshi Kudo, Ming‐Mo Hou, Ana Matilla, Francesco Tovoli, Jennifer J. Knox, Aiwu Ruth He, Bassel F. El‐Rayes, Mirelis Acosta-Rivera, Ho Yeong Lim, Arteid Memaj, Ashwin R. Sama, Chiun Hsu

Article2025

LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.

Richard S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, Shukui Qin, Masafumi Ikeda, Ruocai Xu, Julien Edeline, Baek‐Yeol Ryoo, Zhenggang Ren, Ann‐Lii Cheng, Peter R. Galle, Shuichi Kaneko, Hiromitsu Kumada, Simcha Pollack, Kalgi Mody, Leonid Dubrovsky, David E. Adelberg, Josep M. Llovet

Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study

Abstract

Discussion(0)

Related publications

Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.

A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).

Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial.

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.

LEAP-002 long-term follow-up: Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma.